A 55-year-old patient with COPD complains of increased sputum production and dyspnoea over the last 48 hours. He has a known FEV1 of 40% predicted and is on a long-acting muscarinic antagonist (LAMA). According to UK guidelines, which of the following is the most appropriate initial management for this acute exacerbation?